The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 812-821

  Michaelson, Jennifer S ^a   Kelly, Rebecca ^a   Yang, Lu ^a,b   Zhang, Xiamei ^a,c   Wortham, Kathleen ^a,d   Joseph, Ingrid B J K ^a,e  

^a BIOGEN   (United States)

^b SANOFI   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d Dicerna Pharmaceuticals Inc   (United States)

^e Agensys   (United States)

Author keywords

Breast cancer; Colon cancer; Combination therapy; Fn14; Lung cancer; TWEAK; Xenograft models

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BIIB 036; CARBOPLATIN; FLUOROURACIL; FN14 ANTIBODY; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; STOMACH CANCER; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HALF-LIFE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; PACLITAXEL; RECEPTORS, TUMOR NECROSIS FACTOR; STOMACH NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863454553     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20564     Document Type: Article

References (19)

1. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16:1701-8; PMID:20197482; http://dx.doi. org/10.1158/1078-0432.CCR-09-1692.
2. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010; 16:497-508; PMID:20068083; http:// dx.doi.org/10.1158/1078-0432.CCR- 09-1929.
3. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156:1253-61; PMID:10751351; http://dx.doi.org/10.1016/S0002- 9440(10)64996-6.
4. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. [erratum appears in Cancer Res 2002; 62:4532]. Cancer Res 2002; 62:2890-6; PMID:12019169.
5. Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005; 24:2613-24; PMID:15735761; http://dx.doi. org/10.1038/sj.onc.1208208.
6. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is upregulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003; 162:1313-21; PMID:12651623; http:// dx.doi.org/10.1016/S0002-9440(10)63927-2.
7. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006; 25:3346- 56; PMID:16449976; http://dx.doi.org/10.1038/sj.onc.1209357.
8. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008; 6:725-34; PMID:18505918; http://dx.doi.org/10.1158/1541- 7786.MCR-08-0005.
9. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272:32401-10; PMID:9405449; http://dx.doi.org/10.1074/jbc.272.51.32401.
10. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 2011; 3:362-75; PMID:21697654; http://dx.doi.org/10.4161/mabs.3.4.16090.
11. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, et al. Multiple pathways of TWEAK-induced cell death. J Immunol 2002; 168:734-43; PMID:11777967.
12. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003;170:341-8; PMID:12496418.
13. Schneider P, Schwenzer R, Haas E, Mühlenbeck F, Schubert G, Scheurich P, et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29:1785-92; PMID:10382740; http://dx.doi.org/10. 1002/ (SICI)1521-4141(199906)29:06<1785::AIDIMMU1785>3.0.CO;2-U.
14. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182:171-84; PMID:18606850; http://dx.doi. org/10.1083/jcb.200801010.
15. Wilson CA, Browning JL. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ 2002; 9:1321-33; PMID:12478469; http://dx.doi. org/10.1038/sj.cdd.4401107.
16. Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, et al. Targeting the lymphotoxinbeta receptor with agonist antibodies as a potential cancer therapy. Cancer Res 2006; 66:9617-24; PMID:17018619; http://dx.doi.org/ 10.1158/0008-5472.CAN-06-0217.
17. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21:3526- 34; PMID:12972530; http://dx.doi.org/10.1200/JCO.2003.09.037.
18. Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, et al. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9:2582-92; PMID:20660600; http://dx.doi.org/10.1158/1535- 7163.MCT-10-0370.
19. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652-61; PMID:16899615; http://dx.doi.org/10.1158/1078-0432.CCR-06-0113.